Definitive Healthcare (NASDAQ:DH) Stock Rating Lowered by Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

DH has been the subject of a number of other reports. Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Robert W. Baird set a $1.10 price target on shares of Definitive Healthcare in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Barclays cut their price objective on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research report on Monday, March 30th. Finally, Bank of America reaffirmed an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, Definitive Healthcare has a consensus rating of “Reduce” and a consensus target price of $2.47.

Definitive Healthcare Price Performance

DH stock opened at $0.76 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. The business has a 50 day simple moving average of $0.83 and a 200-day simple moving average of $1.31. The firm has a market capitalization of $80.09 million, a PE ratio of -0.47, a price-to-earnings-growth ratio of 10.11 and a beta of 1.33. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.70.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $55.93 million during the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Equities research analysts anticipate that Definitive Healthcare will post 0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its holdings in Definitive Healthcare by 32.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after buying an additional 4,407 shares during the period. State of Alaska Department of Revenue lifted its position in Definitive Healthcare by 109.3% in the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after buying an additional 5,970 shares during the last quarter. Invesco Ltd. boosted its stake in Definitive Healthcare by 5.8% during the fourth quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock worth $337,000 after buying an additional 6,400 shares during the period. Raymond James Financial Inc. purchased a new position in Definitive Healthcare during the second quarter worth about $32,000. Finally, Creative Planning increased its position in shares of Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after acquiring an additional 8,428 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.